SCHEDULE 13G: C/M Capital Funds Report 0% Stake in Biodexa Pharmaceuticals Plc, Indicating Significant Divestment

Sentiment:

Beneficial Ownership Update 18 February 2025 9:30 PM

📋All filings for Biodexa Pharmaceuticals PLC

C/M Capital Master Fund, LP and its affiliates, including Thomas Walsh and Jonathan Juchno, have filed a Schedule 13G indicating they no longer hold a beneficial ownership stake in Biodexa Pharmaceuticals Plc, reporting 0% ownership.

Worse than expectedThe filing indicates that the Reporting Persons, who previously may have held more than 5% of the Issuer's shares, now report 0% beneficial ownership. This represents a significant reduction or complete divestment of their stake, which could be viewed negatively by the market as a large investor has exited or substantially reduced their position.

Summary

C/M Capital Master Fund, LP, C/M Capital Partners, LP, Thomas Walsh, and Jonathan Juchno (collectively, the "Reporting Persons") have filed a Schedule 13G regarding their beneficial ownership of Biodexa Pharmaceuticals Plc (the "Issuer").
The filing indicates that as of the event date, February 10, 2025, the Reporting Persons may have been deemed to beneficially own more than 5% of the Issuer's Ordinary Shares.
However, the current filing reports an aggregate beneficial ownership of 0% of the class of securities for all Reporting Persons.
The securities in question are Ordinary Shares, nominal value 0.00005 GBP per share, underlying American Depositary Shares (ADSs) of Biodexa Pharmaceuticals Plc, which trade on The Nasdaq Capital Market under the symbol "BDRX" (CUSIP 59564R807).
Each ADS represents 10,000 Ordinary Shares.
The Reporting Persons certify that the securities were not acquired and are not held for the purpose of changing or influencing the control of the Issuer.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative as a significant investor has reduced their stake to 0%, which can be perceived as a lack of confidence or a strategic exit, though the filing itself is purely factual and passive.

Negatives

The filing indicates a complete divestment or reduction below the reporting threshold by C/M Capital Master Fund, LP and its affiliates, suggesting a significant reduction in their investment in Biodexa Pharmaceuticals Plc.

Future Outlook

Industry Context

This filing is a standard disclosure of a change in beneficial ownership by an institutional investor. It does not provide insights into broader industry trends but reflects a specific investment decision by C/M Capital regarding Biodexa Pharmaceuticals Plc.

Stakeholder Impact

Shareholders: May interpret the divestment by C/M Capital as a negative signal, potentially impacting investor confidence and share price.
Company Management: The exit of a significant institutional investor might prompt management to assess investor relations strategies or underlying reasons for the divestment.

Key Dates

Date	Description
02/10/2025	Date of event which required the filing of this statement, when Reporting Persons may have been deemed to beneficially own more than 5% of Ordinary Shares.
02/18/2025	Date the Schedule 13G was signed and filed.

Keywords

Biodexa Pharmaceuticals Plc, BDRX, Schedule 13G, Beneficial Ownership, C/M Capital Master Fund, C/M Capital Partners, Thomas Walsh, Jonathan Juchno, SEC Filing, Divestment, Shareholding Update

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.